Depomed has announced a new launch of Lazanda fentanyl nasal spray in the US for the management of breakthrough pain in cancer patients who get inadequate relief from opioids. The company acquired the product from Archimedes in July 2013. Depomed is offering a new patient support system for the drug that is "designed to streamline patient access" and that includes … [Read more...] about Depomed launches Lazanda fentanyl nasal spray with patient support program
Business
Adasuve inhaled loxapine launched in Austria
Alexza Pharmaceuticals and Grupo Ferrer have launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic patients in Austria, the companies said. Ferrer is working with Vienna-based AOP Orphan Pharmaceuticals to commercialize Adasuve in Austria. Alexza President and CEO Thomas B. King commented, "With the launch of Adasuve in … [Read more...] about Adasuve inhaled loxapine launched in Austria
Settlement in Accuhale suit against AstraZeneca
Acacia Research has announced a settlement in its patent infringement suit against AstraZeneca. The suit, Accuhale vs. AstraZeneca, was filed in December 2011, shortly after Acacia announced that it had acquired patents for inhaler technology from “a major medical company.” No terms were disclosed. The suit claimed that AstraZeneca's Symbicort pMDI infringed on US … [Read more...] about Settlement in Accuhale suit against AstraZeneca
Savara gets $1.7 million for AeroVanc development
Cystic Fibrosis Foundation Therapeutics (CFFT) has awarded Savara Pharmaceuticals $1.7 million for further development of AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. CFFT is a nonprofit affiliate of the Cystic Fibrosis Foundation that supports discovery and development … [Read more...] about Savara gets $1.7 million for AeroVanc development
Insmed provides update on Arikace for NTM
Insmed has announced that it anticipates discussions with the EMA by the end of 2013 regarding Arikace inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial (NTM) lung disease and that it has already initiated the Scientific Advice Working Party (SAWP) process. The company says that it is also looking to take advantage of a "globally … [Read more...] about Insmed provides update on Arikace for NTM
Dance Biopharm to partner with Harmony Asset for inhaled insulin
Under a new joint venture, Harmony Asset will pay development costs for Dance Biopharm's Adagio inhaled insulin in Asian countries, including Korea, India, Indonesia and Australia, Dance has announced. The agreement excludes Japan. Harmony will have majority ownership of the joint venture, and the board of directors will be comprised of an equal number of … [Read more...] about Dance Biopharm to partner with Harmony Asset for inhaled insulin
Nephron recalls albuterol inhalation solution
Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution "as a precautionary measure, due to results from . . . internal monitoring processes." The company says that it has not received reports of reportable adverse events for the 0.083% solution and that the lots met Nephron's quality specifications when … [Read more...] about Nephron recalls albuterol inhalation solution
FDA approves non-prescription Nasacort Allergy 24HR nasal spray
Sanofi has announced today that its Nasacort Allergy 24HR triamcinolone acetonide nasal spray for the treatment of nasal allergies will be available over-the-counter beginning in spring 2014 now that the FDA has approved it as an OTC product. Sanofi's consumer healthcare division, Chattem, Inc. will market the product. An FDA advisory committee recommended approval … [Read more...] about FDA approves non-prescription Nasacort Allergy 24HR nasal spray
Teva announces plans for expanded respiratory business
During a recent web presentation on its respiratory R&D activities, Teva announced that it plans to make 13 regulatory submissions for respiratory products over the next 5 years, introduce "proprietary devices addressing unmet needs," and expand its respiratory business to become "a multi-billion $ franchise by the end of the decade." According to the company, its … [Read more...] about Teva announces plans for expanded respiratory business
Cirrus gets FDA grant for MDI formulation study
The US FDA has awarded a grant to Cirrus Pharmaceuticals for a study titled “Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance,” the company has announced. According to Cirrus, the study will "investigate the effects of excipient concentrations and API particle size on the aerosolization performance of metered dose inhaler (MDI) … [Read more...] about Cirrus gets FDA grant for MDI formulation study